A Comparative Observational Study to Evaluate the Efficacy of Mid-Urethral Sling with Botulinum Toxin A Injection in Urinary Incontinence Patients.
Acetylcholine Release Inhibitors
/ administration & dosage
Administration, Intravesical
Adult
Aged
Botulinum Toxins, Type A
/ administration & dosage
Female
Humans
Middle Aged
Recovery of Function
Retrospective Studies
Suburethral Slings
Treatment Outcome
Urinary Bladder, Overactive
/ diagnosis
Urinary Incontinence
/ diagnosis
Urodynamics
/ drug effects
Urogenital Surgical Procedures
/ adverse effects
antimuscarinics
botulinum toxin A
mid-urethral sling
overactive bladder
urinary incontinence
Journal
Toxins
ISSN: 2072-6651
Titre abrégé: Toxins (Basel)
Pays: Switzerland
ID NLM: 101530765
Informations de publication
Date de publication:
02 06 2020
02 06 2020
Historique:
received:
17
04
2020
revised:
28
05
2020
accepted:
28
05
2020
entrez:
6
6
2020
pubmed:
6
6
2020
medline:
4
3
2021
Statut:
epublish
Résumé
This study aimed to evaluate and compare the efficacy and safety of mid-urethral sling (MUS) with botulinum toxin A (BoNT-A) versus MUS only in women with mixed urinary incontinence. This was a comparative observational study, and total of 73 patients were enrolled. A total of 38 and 35 patients received MUS only and MUS with BoNT-A injection, respectively. The efficacy outcome included change in Urinary Incontinence Outcome Scores (UIOS), change in Overactive Bladder Symptom Score (OABSS), and use of antimuscarinic agent or beta-3 agonist. Safety assessments included adverse events including urinary retention, increased postvoid residual volumes, and urinary tract infection. MUS with BoNT-A injection was insignificantly better than MUS only in urinary incontinence outcome (88% vs. 71%, respectively,
Identifiants
pubmed: 32498306
pii: toxins12060365
doi: 10.3390/toxins12060365
pmc: PMC7354459
pii:
doi:
Substances chimiques
Acetylcholine Release Inhibitors
0
Botulinum Toxins, Type A
EC 3.4.24.69
incobotulinumtoxinA
EC 3.4.24.69
Types de publication
Comparative Study
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Références
Int Urogynecol J. 2011 Oct;22(10):1241-7
pubmed: 21850510
Investig Clin Urol. 2019 Sep;60(5):373-379
pubmed: 31501800
J Urol. 2013 Jun;189(6):2186-93
pubmed: 23246476
Climacteric. 2015;18 Suppl 1:30-6
pubmed: 26366798
JAMA. 2017 Oct 24;318(16):1592-1604
pubmed: 29067433
Int J Gynaecol Obstet. 2004 Jul;86 Suppl 1:S6-16
pubmed: 15302563
Neurourol Urodyn. 2000;19(2):127-35
pubmed: 10679829
Int Urogynecol J Pelvic Floor Dysfunct. 2007 May;18(5):543-9
pubmed: 17036169
J Urol. 2010 Dec;184(6):2416-22
pubmed: 20952013
J Urol. 2016 Sep;196(3):809-18
pubmed: 27063854
Eur Urol. 2013 Aug;64(2):249-56
pubmed: 23608668
Int J Clin Pract. 2014 Oct;68(10):1246-56
pubmed: 24754838
Am J Obstet Gynecol. 2016 Jun;214(6):708.e1-5
pubmed: 27105683
Eur Urol. 2012 Jul;62(1):148-57
pubmed: 22464310
Eur Urol. 2010 Dec;58(6):919-26
pubmed: 20864251
Neurourol Urodyn. 2018 Aug;37(S6):S13-S19
pubmed: 30614063
Eur Urol. 2006 Dec;50(6):1306-14; discussion 1314-5
pubmed: 17049716
Neurourol Urodyn. 2011 Jan;30(1):47-51
pubmed: 21181960
BJU Int. 1999 Jul;84(1):14-5
pubmed: 10444116
Cochrane Database Syst Rev. 2015 Jul 01;(7):CD006375
pubmed: 26130017
Int Urol Nephrol. 2015 Nov;47(11):1779-88
pubmed: 26433883
J Urol. 2015 May;193(5):1572-80
pubmed: 25623739
Rev Urol. 2004;6 Suppl 3:S3-9
pubmed: 16985863
BMC Med. 2017 Mar 24;15(1):63
pubmed: 28335792
Eur J Obstet Gynecol Reprod Biol. 2012 Dec;165(2):347-51
pubmed: 22944381
Eur Urol. 2016 Jul;70(1):136-145
pubmed: 26965560